Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

ebilitating disease," said William H. Ludlam, MD, PhD, Director, Seattle Pituitary Center at the Swedish Neuroscience Institute in Seattle, WA.  "The results of this study suggest that pasireotide may help patients achieve biochemical control of their Cushing's disease and its symptoms by directly targeting the pituitary tumor that triggers excess cortisol production."

PASPORT-CUSHINGS (PASireotide clinical trial PORTfolio - CUSHING'S disease) is the largest randomized study to evaluate a medical therapy in patients with Cushing's disease(1). The trial is part of a large-scale global clinical development program to assess the efficacy and safety of SOM230 in a range of pituitary and neuroendocrine tumors(6).

"Positive results from this trial bring us one step closer to providing physicians with a new treatment option to offer people living with the physically and emotionally debilitating symptoms associated with Cushing's disease," said Herve Hoppenot, President, Novartis Oncology.

These data will form the basis for the first regulatory filing of SOM230 planned this year. SOM230 has orphan drug designation for Cushing's disease in the US and Europe(7),(8). In the US, orphan drugs are those developed to treat diseases affecting fewer than 200,000 people(9). In Europe, orphan drugs are those developed to treat conditions affecting fewer than five in 10,000 people(8).

Study detailsPASPORT-CUSHINGS is a prospective Phase III study of 162 patients conducted at 68 sites in 18 countries. The study evaluated the efficacy and safety of SOM230 in patients with persistent or recurrent Cushing's disease, as well as in patients with newly diagnosed Cushing's disease who are not candidates for surgery(1),(10).

Patients with primarily moderate to severe hypercortisolism were randomized to receive SOM230 subcutaneous (sc) injection in doses of 600ug (n=82) or 900ug (n=80) twice daily. The primary endpoint was the proportion of patients who
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Integrated Silicon Solution, Inc. ... memory and analog IC solutions, today announced that it ... 24, 2014, at 7:00 a.m. Pacific Time (10:00 a.m. ... the fiscal 2014 third quarter ended June 30, 2014. ... dial 1-888-556-4997 before 6:50 a.m. Pacific time on July ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Inc. today announced the completion of subject dosing ... and bioavailability after administration of two proprietary formulations ... collaboration with the University of Minnesota and James ... experts in clinical research of the nasal delivery ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals ... 500 mg, the generic version of Novartis, Famvir® Tablets, a ... sales of approximately $196 million for the 12 months ending ... Currently, Mylan has 165 ANDAs pending FDA approval representing $98.5 ...
Cached Medicine Technology:Neurelis Announces Completion of Dosing in Study of Intranasal Diazepam 2
(Date:7/10/2014)... consuming a supplement of omega 3 fatty acids had ... fats and omega 6 fatty acids, according to Duke ... Annals of the Rheumatic Diseases (10.1136/annrheumdis-2014-205601) on July ... just obesity may contribute to worsening osteoarthritis. , ... significant role than mechanical factors in the link between ...
(Date:7/10/2014)... Denver, Colorado (PRWEB) July 10, 2014 ... countries will gather in Copenhagen this July 13-17 ... discoveries bringing the world closer to breakthroughs in ... is the world’s largest conference of its kind. ... program, AAIC serves as a catalyst for generating ...
(Date:7/10/2014)... July 10, 2014 CBPartners, a global ... has launched a new website. The redesigned site ... increased access to the firm’s thought pieces, blog posts, ... ideal platform to showcase our insights, capabilities, and to ... CBPartners’ Chief Executive Officer, Cyrus Chowdhury. “An enhanced ...
(Date:7/10/2014)... 10, 2014 Parker Waichman LLP, ... rights of victims injured by defective medical devices, ... over allegations that the woman’s hidden, aggressive leiomyosarcoma ... morcellator used during a routine laparoscopic supracervical hysterectomy ... Wolf Medical Instruments Corporation over its Wolf Power ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Nature, not nurture, ... of individual chimpanzees, a new study finds. "As ... comes to cognitive [thinking] abilities in chimpanzees," William Hopkins ... said in a news release from the journal ... insight into the evolution of intelligence in humans, Hopkins, ...
Breaking Medicine News(10 mins):Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:CBPartners Announces New Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Like Humans, Chimps' Smarts May Rely on Genes 2
... ECUBLENS, SWITZERLAND, March 13 /PRNewswire-FirstCall/ - Neurochem,(International) ... (NASDAQ: NRMX ; TSX: NRM), announces ... pursue the drug development program for its ... approval for,the treatment of Amyloid A (AA) ...
... VELCADE, melphalan and prednisone, reported a 32 percent complete remission rate ... ... CAMBRIDGE, Mass., March 13 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ... clinical trial of the combination therapy,VELCADE, melphalan and prednisone (VcMP) in ...
... notes due June 2008 ... expenses going forward Projects Zevalin(R) net ... 13 Seattle-Cell Therapeutics,Inc. (CTI) (Nasdaq: CTIC ; MTA) ... twelve months ended December 31,2007., Recent Events, Announced ...
... Health Parity on Capitol Hill, WASHINGTON, March 12 ... Her Arms (TWLOHA) with the Mental Health Liaison,Group will ... Hill in,room B369 Rayburn House Office Building. It will ... Addiction Equity Act, an important,civil rights victory that begins ...
... Not Good Enough, WASHINGTON, March 12 Today, ... the,health-based National Ambient Air Quality Standard for ozone. We ... cannot. The standard announced,today, although an improvement, falls far ... are unable to celebrate half measures when the risks ...
... Award for ... Innovation in Healthcare Research, SACRAMENTO, Calif., March 12 ... ratios in California,hospitals revealed little impact on patient outcomes in ... the March 2008 issue of,Policy, Politics & Nursing Practice, a ...
Cached Medicine News:Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 2Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 2Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 3Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 5Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 6Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 7Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 4Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 2Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 3Health News:Statement of Bernadette Toomey, President and Chief Executive Officer, American Lung Association 2Health News:Statement of Bernadette Toomey, President and Chief Executive Officer, American Lung Association 3Health News:California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 2Health News:California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 3Health News:California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 4
ThermalSeal RT (5mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates. Will not wrinkle in the freezer....
DMSO-resistant microplate sealing film...
Sealing tape featuring 3M adhesive technology. Opaque and strong. Prevents photo-degradation....
Aluminum Seal, Reflective, Bulk...
Medicine Products: